GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Icecure Medical Ltd (NAS:ICCM) » Definitions » Float Percentage Of Total Shares Outstanding

Icecure Medical (Icecure Medical) Float Percentage Of Total Shares Outstanding : 44.47% (As of May. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Icecure Medical Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Icecure Medical's float shares is 20.34 Mil. Icecure Medical's total shares outstanding is 45.73 Mil. Icecure Medical's float percentage of total shares outstanding is 44.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Icecure Medical's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Icecure Medical's Institutional Ownership is 0.06%.


Icecure Medical Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Icecure Medical's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=20.34/45.73
=44.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Icecure Medical (Icecure Medical) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7 Haeshel Street, Southern Industrial Park, PO Box 3163, Caesarea, ISR, 3079504
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.